Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 376 Polycystic Ovary Syndrome 41 Neoplasm Metastasis 23 Endometrial Neoplasms 22 Ovarian Neoplasms 16 Neoplasms 14 Infertility 12 Advanced Breast Cancer 10 Fallopian Tube Neoplasms 8 Carcinoma, Intraductal, Noninfiltrating 8 Triple Negative Breast Neoplasms 7 Recurrence 7 Osteoporosis 7 Carcinoma, Ductal, Breast 7 Breast Neoplasms, Male 7 Breast Diseases 7 Carcinoma, Lobular 6 Breast Carcinoma In Situ 6 Prostatic Neoplasms 5 Leiomyoma 4 Infertility, Female 4 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Arthralgia 4 Obesity 3 Neoplasms, Hormone-Dependent 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Non-Small-Cell Lung 3 Anovulation 3 Uterine Neoplasms 2

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Invasive Nos × Letrozole × Clear all

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡